Sapio Luigi, Ragone Angela, Spina Annamaria, Salzillo Alessia, Naviglio Silvio
Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples 80138, Italy.
Cancer Drug Resist. 2022 Jun 21;5(3):625-636. doi: 10.20517/cdr.2022.34. eCollection 2022.
The latest scientific knowledge has provided additional insights accountable for the worst prognosis for pancreatic ductal adenocarcinoma (PDAC). Among the causative factors, the aptitude to develop resistance towards approved medications denotes the master key for understanding the lack of improvement in PDAC survival over the years. Even though several compounds have achieved encouraging results at preclinical stage, no new adjuvant agents have reached the bedside of PDAC patients lately. The adiponectin receptor agonist AdipoRon is emerging as a promising anticancer drug in different cancer models, particularly in PDAC. Building on the existing findings, we recently reinforced its candidacy in PDAC cells, proposing AdipoRon either as a suitable partner in gemcitabine-based treatment or as an effective drug in resistant cells. Crossing the current state-of-the-art, herein we provide a critical perspective on AdipoRon to figure out whether this receptor agonist can potentially be considered a future therapeutic choice in overcoming chemotherapy-induced resistance, expressly in PDAC.
最新的科学知识为胰腺导管腺癌（PDAC）最差的预后情况提供了更多见解。在致病因素中，对已获批药物产生耐药性的倾向是理解多年来PDAC生存率未能提高的关键所在。尽管有几种化合物在临床前阶段取得了令人鼓舞的结果，但最近尚无新的辅助药物应用于PDAC患者。脂联素受体激动剂AdipoRon在不同癌症模型中，尤其是在PDAC中，正成为一种有前景的抗癌药物。基于现有研究结果，我们最近进一步证实了它在PDAC细胞中的潜力，提出AdipoRon既可以作为基于吉西他滨治疗的合适搭档，也可以作为耐药细胞中的有效药物。超越当前的技术水平，在此我们对AdipoRon进行批判性审视，以确定这种受体激动剂是否有可能被视为克服化疗诱导耐药性的未来治疗选择，特别是在PDAC中。
